With the end of 2024 approaching, what could be more natural than to figure out the top stocks for the rest of the year?

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

But the story could change for Summit in the not-too-distant future. Summit expects to report top-line results in mid-2025 from a late-stage clinical study evaluating ivonescimab as a second-line ...

Summit Therapeutics (NASDAQ: SMMT) is a biotech stock that few investors have heard of, but it has the makings of a winner ...

At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from , Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

While it remains to be seen how Summit's oncology turn ultimately shakes out, at this point it is indeed looking like a ...